drugset / Trial / NCT02513355
Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
RandomizedSingle-groupOpen-labelTreatment
Summary
Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.
Timeline
- Start
- 2015-02
- Primary completion
- 2017-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Changchun marina | Unknown | 25 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Endostar | Protein / enzyme biologic | 15 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | parapl | Unknown | 5 unknown | — |
| Subject | parapl | Unknown | 6 unknown | — |